Neuroinflammation in Disease: Risk Factors, Management and Outcomes

$95.00

Rebecca K. Dawson (Editor)

Series: Neuroscience Research Progress
BISAC: MED057000

In this book, the link between the modifiable risk factors of neurodegenerative diseases and chronic neuroinflammation are examined, thus highlighting that controlling risk factors is a valid approach for managing neurodegnerative diseases in which neuroinflammation contributes to the disease progression. The mechanisms of inhibition of neuroinflammation by EST and ERAs are discussed, as well as the neuroprotective roles of EST and ERAs in multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and epilepsy. The final chapter focuses on the dynamics of progression in MS patients, and the disease process within contexts of proinflammatory reactivity and interactivity.
(Imprint: Nova Biomedical)

Clear

Details

Table of Contents

Preface

Chapter 1
An Interplay between Neuroinflammation and Modifiable Risk Factors of Alzheimer’s Disease, Parkinson’s Disease and Amyotrophic Lateral Sclerosis
(Stephanie M. Schindler, Lindsay J. Spielman, Caitlin B. Pointer, Wyatt T. Slattery, Ekta Bajwa, Jordan A. McKenzie, Jessica R. Lowry and Andis Klegeris, Department of Biology, University of British Columbia Okanagan Campus, Kelowna, British Columbia, Canada)

Chapter 2
Therapeutic Effects of Estrogen Receptor Agonists in Inhibition of Neuroinflammation in Different Neurological Disorders
(Mrinmay Chakrabarti and Swapan K. Ray, Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, USA)

Chapter 3
Dynamics of Establishment of Proinflammation as Signature Perivascular Injury in Multiple Sclerosis Neuroparenchyma
(Lawrence M. Agius, 27 “BALLARAT”, Guzeppe Caruana Str., Tal-Virtu, Rabat, RBT09, Malta, Department of Pathology, Mater Dei Hospital, University of Malta, Medical School, Msida, Malta)

Index

Additional information

Binding

,